MedTrace Logo

Use of NGS Cell-free Pathogen Test for Identification of Low Risk Fever & Neutropenia in Pediatric Patients

NCT03530072 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2023-02-10

No results posted yet for this study

Summary

Febrile neutropenia is a common complication in pediatric oncology patients. Standard of care requires admission of all patients for intravenous antibiotics until cultures are negative, patients are afebrile and there are signs of bone marrow recovery. This often results in prolonged hospital admissions with significant financial costs, decreased quality of life and potential secondary infections. More recent data suggests it may be possible to identify a "low risk" group that can be discharged prior to signs of bone marrow recovery. At this time, researchers have been unable to identify a model that is safe for early discharge across institutions.

Conditions

Interventions

DIAGNOSTIC_TEST

Karius Test

Next Generation Sequencing

Sponsors & Collaborators

Principal Investigators

  • Catherine Aftandillian, MD · Lucille Packard Children's Hospital/Stanford University

Eligibility

Min Age
1 Year
Max Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-07
Primary Completion
2019-08-01
Completion
2019-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03530072 on ClinicalTrials.gov